Literature DB >> 25493962

Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions.

Alessandra Vultaggio1, Francesca Nencini, Sara Pratesi, Giulia Petroni, Enrico Maggi, Andrea Matucci.   

Abstract

Immunogenicity of biological agents leads to the development of antidrug antibodies (ADA) and it may be associated to hypersensitivity reactions. Immediate infusion reactions occur during or within 1 h after infusion, and their clinical manifestations vary considerably, ranging from mild to severe and life-threatening. Recent studies show that different mechanisms sustain hypersensitivity reactions toward biologics, and the application of novel methods for detecting ADA has demonstrated the involvement of specific IgE isotypes. Considering the severity of the reactions, it is important for clinicians to recognize their symptoms, to know their pathophysiological mechanisms, and to take risk assessment and prophylactic procedures. This review summarizes the clinical manifestations of antibody and nonantibody-mediated reactions as well as the humoral and cellular mechanisms of antidrug responses. Last, the management of patients at risk is discussed. The definition of diagnostic and prophylactic strategies represents an unavoidable need in the management of potentially reactive patients to improve the safety profile of biologics.

Entities:  

Year:  2014        PMID: 25493962     DOI: 10.1089/jir.2012.0139

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

Review 1.  Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.

Authors:  Courtney E Heron; Rima I Ghamrawi; Esther A Balogh; Steven R Feldman
Journal:  Am J Clin Dermatol       Date:  2020-11-09       Impact factor: 7.403

Review 2.  Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

Authors:  Emilie M J van Brummelen; Willeke Ros; Gertjan Wolbink; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2016-07-20

Review 3.  Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Authors:  Murli Krishna; Steven G Nadler
Journal:  Front Immunol       Date:  2016-02-02       Impact factor: 7.561

4.  Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.

Authors:  Naoto Azuma; Kiyoshi Matsui; Naoaki Hashimoto; Takahiro Yoshikawa; Hajime Sano
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

Review 5.  Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.

Authors:  Nadia M T Roodenrijs; Paco M J Welsing; Joël van Roon; Jan L M Schoneveld; Marlies C van der Goes; György Nagy; Michael J Townsend; Jacob M van Laar
Journal:  Rheumatology (Oxford)       Date:  2022-08-30       Impact factor: 7.046

6.  Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.

Authors:  Anders H Kverneland; Christian Enevold; Marco Donia; Lars Bastholt; Inge Marie Svane; Claus H Nielsen
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.